RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Xiaohe Yang to Antineoplastic Agents

This is a "connection" page, showing publications Xiaohe Yang has written about Antineoplastic Agents.
Connection Strength

2.409
  1. Gant DMA, Parris AB, Yang X. Metformin-induced downregulation of c-Met is a determinant of sensitivity in MDA-MB-468 breast cancer cells. Biochem Biophys Res Commun. 2022 07 12; 613:100-106.
    View in: PubMed
    Score: 0.489
  2. Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Sci Rep. 2018 05 01; 8(1):6829.
    View in: PubMed
    Score: 0.371
  3. Zhao Q, Parris AB, Howard EW, Zhao M, Ma Z, Guo Z, Xing Y, Yang X. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice. Sci Rep. 2017 09 12; 7(1):11306.
    View in: PubMed
    Score: 0.355
  4. Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 2017 02 13; 36(1):28.
    View in: PubMed
    Score: 0.341
  5. Ma Z, Parris AB, Xiao Z, Howard EW, Kosanke SD, Feng X, Yang X. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 2017 01 06; 36(1):6.
    View in: PubMed
    Score: 0.338
  6. Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol. 2007 Oct; 31(4):867-74.
    View in: PubMed
    Score: 0.178
  7. Yang S, Zhou Q, Yang X. Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta. 2007 Jun; 1773(6):903-11.
    View in: PubMed
    Score: 0.172
  8. Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin (Shanghai). 2018 Feb 01; 50(2):133-143.
    View in: PubMed
    Score: 0.091
  9. Turbov JM, Twaddle GM, Yang X, Liu NM, Murthy S. Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro. J Surg Oncol. 2002 Jan; 79(1):17-29.
    View in: PubMed
    Score: 0.030
  10. Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer. 2013 Nov 11; 12(1):134.
    View in: PubMed
    Score: 0.017
  11. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. 2011 Sep 01; 10(17):2959-66.
    View in: PubMed
    Score: 0.015
  12. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010 Feb 01; 70(3):1204-14.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support